For instance, the expression of E-cadherin, Cyclin-Dependent Kinase Inhibitor 1A (p21) and human Bcl-2-associated X protein (hBax) in bladder urothelial carcinoma cells, the silencing of endogenous Cyclin-Dependent Kinase 11 (CDK11) gene expression in osteosarcoma cell line, and the knockout of the SHC binding and spindle associated 1 (SHCBP1) gene in breast cancer cells using the CRISPR/Cas9 system have proven effective in reducing cancer progression19–21. The gene discussed is CDKN1A; the disease is bladder transitional cell carcinoma.